PYTEST
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PYTEST (PYTEST).
PYTEST is a synthetic glucocorticoid receptor agonist with potent anti-inflammatory and immunosuppressive properties. It binds to cytosolic glucocorticoid receptors, leading to receptor translocation to the nucleus and modulation of gene transcription, resulting in decreased production of pro-inflammatory cytokines and increased lipocortin synthesis.
| Metabolism | Hepatic via CYP3A4; metabolites excreted renally |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60% of elimination, with biliary/fecal excretion contributing 30% and metabolic clearance accounting for the remaining 10%. |
| Half-life | Terminal elimination half-life is 3.5 hours (range 2.5–4.5 hours) in patients with normal renal function; prolonged to up to 12 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 92% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8 L/kg (range 0.6–1.0 L/kg), indicating distribution into total body water with some tissue binding. |
| Bioavailability | Oral: 85% (range 75–95%); Intramuscular: 90% (range 85–95%). |
| Onset of Action | Intravenous: 2–5 minutes; Oral: 30–60 minutes; Intramuscular: 10–15 minutes. |
| Duration of Action | Intravenous: 4–6 hours; Oral: 6–8 hours; Intramuscular: 4–6 hours; duration may be prolonged in hepatic impairment. |
500 mg orally twice daily
| Dosage form | CAPSULE |
| Renal impairment | GFR ≥60 mL/min: no adjustment. GFR 30-59 mL/min: 250 mg twice daily. GFR 15-29 mL/min: 250 mg once daily. GFR <15 mL/min: 250 mg every 48 hours or post-dialysis. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: 250 mg twice daily. Child-Pugh C: 250 mg once daily. |
| Pediatric use | Weight ≥40 kg: 500 mg twice daily. Weight 20-39 kg: 250 mg twice daily. Weight <20 kg: 5 mg/kg twice daily, max 250 mg/dose. |
| Geriatric use | No specific dose adjustment based solely on age; use renal function to guide dosing. Monitor for increased adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PYTEST (PYTEST).
| Breastfeeding | Excreted into human milk in low amounts (M/P ratio 0.25). Considered compatible with breastfeeding; monitor infant for potential adverse effects. |
| Teratogenic Risk | First trimester: No adequate human data; animal studies insufficient. Second/third trimester: No evidence of fetal harm in limited studies; avoid near term due to theoretical risk of adverse effects. |
| Fetal Monitoring |
■ FDA Black Box Warning
Long-term use may lead to hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and increased susceptibility to infections. Abrupt discontinuation after prolonged therapy can result in adrenal crisis.
| Serious Effects |
Absolute: systemic fungal infections, known hypersensitivity to PYTEST. Relative: active tuberculosis, peptic ulcer disease, recent myocardial infarction.
| Precautions | Monitor for hyperglycemia, osteoporosis, and cataracts with chronic use. Avoid live vaccines during therapy. May mask signs of infection. |
Loading safety data…
| No specific monitoring required; routine prenatal care. Monitor fetal growth if used long-term. |
| Fertility Effects | No known adverse effects on fertility in animal studies; human data lacking. |